…or are collaborative deals among Big Pharma a compulsion?

IIPM, ADMISSIONS FOR NEW DELHI & GURGAON BRANCHES

So, what’s unusual in that? The question pours in. No doubt, these big pharma companies have been shelling out billions in the past to acquire companies to channel new ideas. But as a unitary force, allthese companies have found themselves wanting in more ways than one, as their blockbuster patents are on the brink of extinction. And it seems better to combine forces rather than becoming dinosaurs themselves. “Well thought of”, answers Sujay Shetty, Associate Director, Pharmaceutical and Life Sciences practice, Pricewaterhouse- Coopers. “With the dearth of new compounds in the pipeline and patents expiring on various blockbusters, collaborative deals with their peers seems to be a smart strategy from Big Pharma,” says he. Undoubtedly a good rationale in support of these blissful marriages, but then one cannot deny the need for vigour either. Raison d’être, poor financial performance, rising sales & marketing expenditures, increased legal & regulatory constraints & challenges and tarnished reputations at times because of drug failures.

For more articles, Click on IIPM Article

Source : IIPM Editorial, 2008

An IIPM and Professor Arindam Chaudhuri (Renowned Management Guru and Economist) Initiative

For More IIPM Info, Visit below mentioned IIPM articles.
IIPM, GURGAON
ARINDAM CHAUDHURI’S 4 REASONS WHY YOU SHOULD CHOOSE IIPM...
IIPM Economy Review